TY - JOUR T1 - Gut microbiome activity predicts risk of type 2 diabetes and metformin control in a large human cohort JF - medRxiv DO - 10.1101/2021.08.13.21262051 SP - 2021.08.13.21262051 AU - Nan Shen AU - Nevenka Dimitrova AU - Cleo H. Ho AU - Pedro J. Torres AU - Francine R Camacho AU - Ying Cai AU - Momchilo Vuyisich AU - Damon Tanton AU - Guruduth Banavar Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/18/2021.08.13.21262051.abstract N2 - Recognizing and treating the early stages of type 2 diabetes (T2D) is the most cost effective way to decrease prevalence, before heart disease, renal disease, blindness, and limb amputation become inevitable. In this study, we employ high resolution gut microbiome metatranscriptomic analysis of stool samples from 53,970 individuals to identify predictive biomarkers of type 2 diabetes progression and potential for diagnosis and treatment response. The richness of the metatranscriptomic data enabled us to develop a T2D risk model to delineate individuals with glycemic dysregulation from those within normal glucose levels, with ROC-AUC of 0.83+/-0.04. This risk score can predict the probability of having insulin dysregulation before detecting high glycated hemoglobin (HbA1c), the standard-of-care marker for prediabetes and diabetes. Additionally, a machine learning model was able to distinguish novel metatranscriptomic features that segregate patients who receive metformin and are able to control their HbA1c from those who do not. These discoveries set the stage for developing multiple therapeutic avenues for prevention and treatment of T2D.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by Viome Life Sciences Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Viome IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary data is available within the Article and Supplementary Information. Research requiring additional data can visit https://www.viome.com/vri/data-access, through which we provide access to summary statistics through a Data Transfer Agreement that protects the privacy of our participants' data. ER -